S-1 maintenance therapy after first-line treatment with nab-paclitaxel plus s-1 for advanced pancreatic adenocarcinoma: a real-world study

HIGHLIGHTS

• who: Yan Shi and colleagues from the West Virginia University, United States have published the research work: S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study, in the Journal: (JOURNAL)
• what: The main reason for the refractoriness of local primary PDAC is that pancreatic cancer cells are surrounded by an intense desmoplastic reaction which may create a barrier to the drugs penetrating into the tumor and the stroma has been addressed as a potential therapeutic target. For APAC where cure is scarce . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.